Literature DB >> 29091270

A high throughput method to study the physiology of E2:ERα signaling in breast cancer cells.

Stefano Leone1, Claudia Busonero1, Filippo Acconcia1.   

Abstract

17β-estradiol (E2) regulates diverse physiological effects including cell proliferation through the estrogen receptor α (ERα), which as a transcription factor drives gene transcription and as an extra-nuclear localized receptor triggers the membrane-dependent activation of diverse kinase cascades. E2 also modifies ERα intracellular levels via diverse intracellular mechanisms. In this way, the E2-acivated ERα integrates signaling cascades with the modulation of receptor intracellular concentration and with the induction of DNA synthesis and ultimately drives cell proliferation. In turn, E2 signaling deregulation can cause many diseases including breast cancer (BC). Recently, we performed a Western blotting (WB)-based screen to identify novel pathways affecting ERα intracellular levels and BC cell proliferation. However, because WB lacks high throughput potential, a high-content method to detect all aspects of E2:ERα signaling (nuclear and extra-nuclear receptor activity, ERα levels, E2-induced DNA synthesis) is desirable. Here, we set up a rapid way to measure E2:ERα signaling in 96-well plate format. To demonstrate its robustness, we also challenged 4OH-tamoxifen resistant (Tam-Res) BC cells with a library of anti-cancer drugs and identified methotrexate (MTX) as a molecule inducing ERα degradation and preventing BC cell proliferation. Overall, our research provides a high-content technique to study the physiology of E2:ERα signaling in cells and further suggests a possible anti-ERα and anti-proliferative use for MTX in Tam-Res BCs.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  4OH-tamoxifen; breast cancer; drug screening; estrogen receptor; methotrexate

Mesh:

Substances:

Year:  2017        PMID: 29091270     DOI: 10.1002/jcp.26251

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.

Authors:  Claudia Busonero; Stefano Leone; Fabrizio Bianchi; Filippo Acconcia
Journal:  Cell Oncol (Dordr)       Date:  2018-09-04       Impact factor: 6.730

2.  Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.

Authors:  Stefania Bartoloni; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

3.  Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Authors:  Sara Pescatori; Stefano Leone; Manuela Cipolletti; Stefania Bartoloni; Alessandra di Masi; Filippo Acconcia
Journal:  J Exp Clin Cancer Res       Date:  2022-04-13

4.  The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.

Authors:  Stefania Bartoloni; Stefano Leone; Sara Pescatori; Manuela Cipolletti; Filippo Acconcia
Journal:  Mol Oncol       Date:  2022-09-03       Impact factor: 7.449

5.  Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.

Authors:  Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

Review 6.  ERα, A Key Target for Cancer Therapy: A Review.

Authors:  Yanfang Liu; Hong Ma; Jing Yao
Journal:  Onco Targets Ther       Date:  2020-03-11       Impact factor: 4.147

7.  A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.

Authors:  Manuela Cipolletti; Stefania Bartoloni; Claudia Busonero; Martina Parente; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.